- Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
-
Kim JJ, Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS
- KMID: 2522956
- Clin Psychopharmacol Neurosci.
- 2021 Nov;19(4):600-609.
- doi: 10.9758/cpn.2021.19.4.600
The mainstay of schizophrenia treatment is pharmacological therapy using various antipsychotics including first- and second-generation antipsychotics which have different pharmacokinetic and pharmacodynamic property leading to differential presentation of adverse events... -
- CITED
-
- Close
- SHARE
-
- Close
- Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
-
Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS
- KMID: 2519542
- Clin Psychopharmacol Neurosci.
- 2021 Aug;19(3):434-448.
- doi: 10.9758/cpn.2021.19.3.434
Antipsychotic monotherapy (APM) is considered best-acceptable treatment option regardless of antipsychotic class and formulation types for treating schizophrenia. However, antipsychotic polypharmacy (APP) has been also widely utilized in routine clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
-
Wang SM, Kim NY, Na HR, Lim HK, Woo YS, Pae CU, Bahk WM
- KMID: 2516186
- Clin Psychopharmacol Neurosci.
- 2021 May;19(2):341-354.
- doi: 10.9758/cpn.2021.19.2.341
Objective: We performed a meta-analysis of randomized double-blinded placebo controlled trials (DB-RCTs) to investigate efficacy and safety of intranasal esketamine in treating major depressive disorder (MDD) including treatment resistant depression... -
- CITED
-
- Close
- SHARE
-
- Close
- Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
-
Shin C, Pae CU, Kwak KP, Jeon SW, Jeong HG, Kim JW, Lee YJ, Patkar AA, Han C
- KMID: 2516176
- Clin Psychopharmacol Neurosci.
- 2021 May;19(2):243-253.
- doi: 10.9758/cpn.2021.19.2.243
Objective: Many patients with major depressive disorder (MDD) suffer from residual symptoms without achieving remission. However, pharmacologic options for residual symptoms of MDD have been limited. This study aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
-
Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS
- KMID: 2516175
- Clin Psychopharmacol Neurosci.
- 2021 May;19(2):233-242.
- doi: 10.9758/cpn.2021.19.2.233
Objective: In a number of controlled clinical trials and naturalistic studies, aripiprazole once monthly (AOM) has been found to be effective and safe as acute and maintenance treatment options for... -
- CITED
-
- Close
- SHARE
-
- Close
- A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
-
Lee KH, Bahk WM, Lee SJ, Serretti A, Pae CU
- KMID: 2513402
- Clin Psychopharmacol Neurosci.
- 2021 Feb;19(1):160-165.
- doi: 10.9758/cpn.2021.19.1.160
Objective: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice. Methods: Nine patients were prescribed NeuropharmagenⓇ for selection of... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics
-
Kang SG, Cho SE, Na KS, Pae CU, Cho SJ
- KMID: 2513397
- Clin Psychopharmacol Neurosci.
- 2021 Feb;19(1):117-124.
- doi: 10.9758/cpn.2021.19.1.117
Objective: The response to antipsychotics in patients with schizophrenia is still unsatisfactory. Therefore, augmentation with other antipsychotics is common in clinical situations. The purpose of this study was to evaluate... -
- CITED
-
- Close
- SHARE
-
- Close
- Possible Modulatory Role of ARC Gene Variants in Mood Disorders
-
Crisafulli C, Calabrò M, Mandelli L, Wang SM, Lee SJ, Han C, Patkar A, Masand P, Pae CU, Souery D, Mendlewicz J, Serretti A
- KMID: 2513389
- Clin Psychopharmacol Neurosci.
- 2021 Feb;19(1):46-52.
- doi: 10.9758/cpn.2021.19.1.46
Objective: The genetic background of mood disorders is gradually emerging through the use of large multicenter samples but a detailed phenotyping is complementary in elucidating the role of modulating variants. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
-
Han Cs, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Mandelli L, Pae CU, Serretti A
- KMID: 2508991
- Clin Psychopharmacol Neurosci.
- 2020 Nov;18(4):641.
- doi: 10.9758/cpn.2020.18.4.641
-
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice
-
Lee KH, Bahk WM, Lee SJ, Pae CU
- KMID: 2508987
- Clin Psychopharmacol Neurosci.
- 2020 Nov;18(4):621-626.
- doi: 10.9758/cpn.2020.18.4.621
Objective: To test clinical effectiveness and tolerability of Korean Red Ginseng augmentation (RGA) in major depressive disorder (MDD) patients with difficult-to-treat. Methods: Thirty six patients were enrolled in this 6 weeks,... -
- CITED
-
- Close
- SHARE
-
- Close
- Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
-
Pae CU
- KMID: 2506825
- Chonnam Med J.
- 2020 Sep;56(3):157-165.
- doi: 10.4068/cmj.2020.56.3.157
Antipsychotics have been utilized as the standard treatment for schizophrenia regardless of illness phase where antipsychotic monotherapy (APM) is routinely recommended as the gold standard rather than antipsychotic polypharmacy (APP).... -
- CITED
-
- Close
- SHARE
-
- Close
- The Usefulness and Clinical Characteristics of Antidepressant Use for Stroke Patients with Rehabilitation Program: An Exploratory Analysis
-
Lee KH, Park GY, Bahk WM, Lee SJ, Pae CU
- KMID: 2505677
- Clin Psychopharmacol Neurosci.
- 2020 Aug;18(3):445-449.
- doi: 10.9758/cpn.2020.18.3.445
Objective: There has been a lack of data regarding the usefulness and clinical characteristic between patients-treated with and without antidepressants (Pw/Pwo ADs). Methods: One hundred and eighty inpatients were recruited and... -
- CITED
-
- Close
- SHARE
-
- Close
- ZNF804A Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders
-
Calabrò M, Mandelli L, Crisafulli C, Nicola MD, Colombo R, Janiri L, Lee SJ, Jun TY, Wang SM, Masand PS, Patkar AA, Han C, Pae CU, Serretti A
- KMID: 2502148
- Clin Psychopharmacol Neurosci.
- 2020 May;18(2):231-240.
- doi: 10.9758/cpn.2020.18.2.231
Objective: Genetic variations in the gene encoding zinc finger protein 804A gene (ZNF804A) have been associated with major depression and bipolar disorder. In this work we focused on the potential... -
- CITED
-
- Close
- SHARE
-
- Close
- Taking a Responsibility for Future Progression of Clinical Psychopharmacology and Neuroscience
-
Pae CU
- KMID: 2502142
- Clin Psychopharmacol Neurosci.
- 2020 May;18(2):172-173.
- doi: 10.9758/cpn.2020.18.2.172
-
- CITED
-
- Close
- SHARE
-
- Close
- Contribution of Personality Traits,Psychological Factors, and Health-Related Qualityof Life to Medication Adherence in Patientswith Rheumatoid Arthritis
-
Ko KM, Moon SJ, Koh JH, Pae CU, Min JK
- KMID: 2500078
- Yonsei Med J.
- 2020 May;61(5):406-415.
- doi: 10.3349/ymj.2020.61.5.406
Purpose: This study sought to investigate the associations between personality traits and medication adherence and to identify predictors of good medication adherence in rheumatoid arthritis (RA) patients. Materials and Methods: A total... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
-
Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS
- KMID: 2502137
- Clin Psychopharmacol Neurosci.
- 2020 Feb;18(1):153-158.
- doi: 10.9758/cpn.2020.18.1.153
Objective: This study was done for collection of real world data of Aripiprazole Once Monthly (AOM) in patients with schizophrenia. Methods: The observation was up to 12 months from the first... -
- CITED
-
- Close
- SHARE
-
- Close
- The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
-
Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Pae CU
- KMID: 2464715
- Clin Psychopharmacol Neurosci.
- 2019 Nov;17(4):495-502.
- doi: 10.9758/cpn.2019.17.4.495
OBJECTIVE: The present study aimed to observe potential benefit of aripiprazole augmentation in the treatment of major depressive disorder with mixed specifier (MDDM) in naturalistic treatment setting. METHODS: Data were collected... -
- CITED
-
- Close
- SHARE
-
- Close
- Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1
-
Calabrò M, Mandelli L, Crisafulli C, Lee SJ, Jun TY, Wang SM, Patkar AA, Masand PS, Han C, Pae CU, Serretti A
- KMID: 2457399
- Clin Psychopharmacol Neurosci.
- 2019 Aug;17(3):364-368.
- doi: 10.9758/cpn.2019.17.3.364
OBJECTIVE: Genetics factors are likely to play a role in the risk, clinical presentation and treatment outcome in major depressive disorder (MDD). In this study, we investigated the role of... -
- CITED
-
- Close
- SHARE
-
- Close
- Posttraumatic Embitterment Disorder in Patients with Chronic Kidney Disease
-
Lee K, Song HC, Choi EJ, Pae CU, Kim YK
- KMID: 2456721
- Clin Psychopharmacol Neurosci.
- 2019 Mar;17(2):183-188.
- doi: 10.9758/cpn.2019.17.2.183
OBJECTIVE: Posttraumatic embitterment disorder (PTED), a subgroup of an adjustment disorder, is a feeling with anger and helplessness. Hemodialysis may be a trigger event leading to PTED. We investigated the... -
- CITED
-
- Close
- SHARE
-
- Close
- Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
-
Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU
- KMID: 2432263
- Chonnam Med J.
- 2019 Jan;55(1):73-73.
- doi: 10.4068/cmj.2019.55.1.73
The Acknowledgement was published incorrectly. -
- CITED
-
- Close
- SHARE
-
- Close
